ARTICLE | Company News
BioSante, Cold Genesys deal
November 22, 2010 8:00 AM UTC
Cold Genesys received exclusive, worldwide rights to develop and commercialize BioSante's oncolytic virus technology, including CG0070. BioSante received a 19.9% ownership of Cold Genesys, a $95,000 ...